Navigation Links
BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Date:8/30/2010

NOVATO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.  An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

"Receiving orphan drug designation from the FDA for BMN-701 is a significant milestone for our Pompe program.  As part of their assessment for designation, the FDA determined that BMN-701 is sufficiently different from alglusidase alfa (Myozyme/Lumizyme) to allow for a unique orphan designation.  For this reason, clinical superiority over alglusidase alfa will not be necessary to secure orphan exclusivity for BMN-701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "This emphasizes our mission of developing innovative, products for orphan diseases with an unmet medical need.  We believe BMN-701 has the potential to possibly deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches using the recently acquired GILT technology."  

About Pompe DiseasePompe disease, a lysosomal storage disorder, is a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle.  It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase which leads to the accumulation of glycogen in myocyte lysosomes and results in cell death.  The incidence is one in 40,000 births.  There are two main forms of Pompe disease: adult onset with an incidence of one in 57,000 births and infantile onset with an incidence of one in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 /PRNewswire/ ... ABBV ) announced today an extension of their ... will fund and complete a Phase 2 program in ... into Phase 3.  Upon successful completion of the study, ... million.  The terms of the collaboration extension are in ...
(Date:5/16/2013)... May 16, 2013  Today, the National Patient Advocate ... House of Representatives recently approved a bill that ... charging patients higher out-of-pocket fees for newer, more expensive ... which have more severe side-effects. However, the bill was ... which will continue to be a barrier to patients ...
(Date:5/16/2013)...  Amgen (NASDAQ: AMGN ) will participate in ... 2013, at the Sheraton New York Times Square in ... Eastern Daylight Time. Joseph P. Miletich , ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... June 17 Neurocrine Biosciences, Inc. (Nasdaq: ... worldwide collaboration with Boehringer Ingelheim to research and develop ... II diabetes and other indications.  The companies will work ...  Boehringer Ingelheim is responsible for the global development and ...
... June 17, 2010 The Medical Device practice at,MarketsandMarkets is pleased to ... , India , China (BRIC) 2010 - 2015. , ... Browse in-depth TOC on ... China (BRIC) 2010 - 2015 Market Report. Early buyers will receive 10%,customization ...
Cached Medicine Technology:-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes 2-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes 3Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 2Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 3Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 4
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
(Date:5/18/2013)... May 18, 2013 The “Sleep Apnea ... Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal ... to 2017” analyzes and studies the major market drivers, ... Rest of the World. , Browse , ... 16 Figures , 318 pagesand ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The Ayurvedic ... ayurvedic education institution in the West. Program is available ... , Ayurveda is a healing modality practiced for over ... it is considered that health begins when an individual ... understanding of their individual needs. Ayurveda aims to heal ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
(Date:5/18/2013)... 18, 2013 The topics that will be ... framework, scrum roles, scrum meetings, scrum artifacts, and scrum simulation ... for attending them. , These trainings are suitable for business ... ideal for those who will be a part of the ... want to explore Agile and Scrum, but are unsure of ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
... -- Seniors in long-term care facilities have a roughly ... they visit a hospital emergency department in the fall, ... Canadian researchers looked at 1,269 elderly residents of 22 ... Riviere-du-Loup, Quebec between September 2006 and May 2008. ...
... as simple as developing a taste for yerba mate tea? ... human colon cancer cells die when they are exposed to ... of this brew, which has long been consumed in South ... mate tea not only induced death in human colon cancer ...
... OAK BROOK, Ill. January 23, 2012 ... colonoscopy reporting in daily clinical practice and evaluated ... colonoscopy reporting varied significantly in clinical practice. Colonoscopy ... between endoscopy departments was found. Researchers concluded that ...
... forward. A trip to the Emergency Department (ED) is every ... a result of your child,s visit could help a child ... and his research team of leading pediatric emergency physicians at ... and the impact of their research is today recognized as ...
... -- A Kansas State University professor is turning to nutrition ... human nutrition, is helping men make more informed diet decisions ... risk of prostate cancer. Prostate cancer is one of the ... States. "I,m interested in researching ways to prevent prostate ...
... in the blood may signal a risk two times higher ... to medical researchers. "Past studies (in cadavers) have ... from individuals with cancer have higher lead levels," said Emily ... "But prior to this study, the identification of higher lead ...
Cached Medicine News:Health News:Certain Seniors at Risk for Infection After ER Visit: Study 2Health News:Compounds in mate tea induce death in colon cancer cells 2Health News:Study examines quality of colonoscopy reporting and performance 2Health News:Study examines quality of colonoscopy reporting and performance 3Health News:Study examines quality of colonoscopy reporting and performance 4Health News:Pediatric emergency research team hit the mark 2Health News:Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer 2Health News:Lead blood levels may increase smokers' risk for kidney cancer 2Health News:Lead blood levels may increase smokers' risk for kidney cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: